JPWO2020210418A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210418A5 JPWO2020210418A5 JP2021559978A JP2021559978A JPWO2020210418A5 JP WO2020210418 A5 JPWO2020210418 A5 JP WO2020210418A5 JP 2021559978 A JP2021559978 A JP 2021559978A JP 2021559978 A JP2021559978 A JP 2021559978A JP WO2020210418 A5 JPWO2020210418 A5 JP WO2020210418A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- pharmaceutical composition
- day
- cycle
- cycles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 16
- 229960004641 rituximab Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229940125904 compound 1 Drugs 0.000 claims 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 5
- 201000003444 follicular lymphoma Diseases 0.000 claims 5
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833432P | 2019-04-12 | 2019-04-12 | |
| US62/833,432 | 2019-04-12 | ||
| PCT/US2020/027358 WO2020210418A1 (en) | 2019-04-12 | 2020-04-09 | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527398A JP2022527398A (ja) | 2022-06-01 |
| JPWO2020210418A5 true JPWO2020210418A5 (enExample) | 2023-04-17 |
| JP7562557B2 JP7562557B2 (ja) | 2024-10-07 |
Family
ID=70465546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559978A Active JP7562557B2 (ja) | 2019-04-12 | 2020-04-09 | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用する非ホジキンリンパ腫の処置方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11390617B2 (enExample) |
| EP (1) | EP3952880B1 (enExample) |
| JP (1) | JP7562557B2 (enExample) |
| CN (1) | CN114144182B (enExample) |
| AR (1) | AR119715A1 (enExample) |
| AU (1) | AU2020270917B2 (enExample) |
| BR (1) | BR112021020372A2 (enExample) |
| CA (1) | CA3132538A1 (enExample) |
| CL (1) | CL2021002651A1 (enExample) |
| DK (1) | DK3952880T3 (enExample) |
| FI (1) | FI3952880T3 (enExample) |
| HR (1) | HRP20251668T1 (enExample) |
| IL (1) | IL287145A (enExample) |
| LT (1) | LT3952880T (enExample) |
| MA (1) | MA55608A (enExample) |
| MX (1) | MX2021012507A (enExample) |
| PT (1) | PT3952880T (enExample) |
| RS (1) | RS67593B1 (enExample) |
| SG (1) | SG11202111232RA (enExample) |
| SI (1) | SI3952880T1 (enExample) |
| SM (1) | SMT202600013T1 (enExample) |
| TW (1) | TWI853014B (enExample) |
| WO (1) | WO2020210418A1 (enExample) |
| ZA (1) | ZA202107668B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| BR112022007417A2 (pt) | 2019-10-21 | 2022-07-12 | Celgene Corp | Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona |
| US11583536B2 (en) * | 2019-10-21 | 2023-02-21 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
| AU2020370039B2 (en) * | 2019-10-21 | 2026-02-19 | Celgene Corporation | Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same |
| MX2022004688A (es) * | 2019-10-21 | 2022-05-10 | Celgene Corp | Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona. |
| CA3154510A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| CN114929686A (zh) * | 2019-10-21 | 2022-08-19 | 新基公司 | 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮及其盐的固体形式，以及含有其的组合物及它们的用途 |
| JP2024513054A (ja) * | 2021-03-29 | 2024-03-21 | ジュノー セラピューティクス インコーポレイテッド | リンパ腫の治療のためのｃａｒ ｔ細胞療法および免疫調節化合物の組合せ |
| JP2024515108A (ja) * | 2021-04-21 | 2024-04-04 | セルジーン コーポレーション | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用して非ホジキンリンパ腫を治療する方法 |
| CN117279640A (zh) * | 2021-04-21 | 2023-12-22 | 新基公司 | 使用组合疗法治疗b细胞淋巴瘤的方法 |
| MX2023014510A (es) | 2021-06-21 | 2024-01-29 | Celgene Corp | Procesos para la preparacion de (s)-2-(2,6-dioxopiperidin-3-il)-4- ((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoind olin-1,3-diona. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2430669C (en) | 2000-11-30 | 2011-06-14 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| RU2009114159A (ru) * | 2006-09-15 | 2010-10-20 | Селджин Корпорейшн (Us) | N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения |
| EP3199149A1 (en) | 2009-05-19 | 2017-08-02 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| PL2536706T3 (pl) * | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| US20140221427A1 (en) * | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
| JP6347782B2 (ja) * | 2012-08-09 | 2018-06-27 | セルジーン コーポレイション | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| AU2013337352A1 (en) | 2012-11-05 | 2015-05-21 | Celgene Corporation | Treatment of cancer with pomalidomide in a renally impaired subject |
| SG11201507759WA (en) * | 2013-04-02 | 2015-10-29 | Celgene Corp | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| NZ731789A (en) | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| WO2019014100A1 (en) * | 2017-07-10 | 2019-01-17 | Celgene Corporation | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF |
| SG11202009237XA (en) * | 2018-04-23 | 2020-10-29 | Celgene Corp | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
-
2020
- 2020-04-08 AR ARP200101015A patent/AR119715A1/es unknown
- 2020-04-09 MX MX2021012507A patent/MX2021012507A/es unknown
- 2020-04-09 WO PCT/US2020/027358 patent/WO2020210418A1/en not_active Ceased
- 2020-04-09 BR BR112021020372A patent/BR112021020372A2/pt not_active Application Discontinuation
- 2020-04-09 JP JP2021559978A patent/JP7562557B2/ja active Active
- 2020-04-09 PT PT207221805T patent/PT3952880T/pt unknown
- 2020-04-09 CA CA3132538A patent/CA3132538A1/en active Pending
- 2020-04-09 TW TW109112033A patent/TWI853014B/zh active
- 2020-04-09 HR HRP20251668TT patent/HRP20251668T1/hr unknown
- 2020-04-09 RS RS20251313A patent/RS67593B1/sr unknown
- 2020-04-09 EP EP20722180.5A patent/EP3952880B1/en active Active
- 2020-04-09 CN CN202080043197.0A patent/CN114144182B/zh active Active
- 2020-04-09 SG SG11202111232RA patent/SG11202111232RA/en unknown
- 2020-04-09 US US16/844,407 patent/US11390617B2/en active Active
- 2020-04-09 DK DK20722180.5T patent/DK3952880T3/da active
- 2020-04-09 FI FIEP20722180.5T patent/FI3952880T3/fi active
- 2020-04-09 SM SM20260013T patent/SMT202600013T1/it unknown
- 2020-04-09 AU AU2020270917A patent/AU2020270917B2/en active Active
- 2020-04-09 SI SI202030706T patent/SI3952880T1/sl unknown
- 2020-04-09 LT LTEPPCT/US2020/027358T patent/LT3952880T/lt unknown
- 2020-04-09 MA MA055608A patent/MA55608A/fr unknown
-
2021
- 2021-10-08 CL CL2021002651A patent/CL2021002651A1/es unknown
- 2021-10-10 IL IL287145A patent/IL287145A/en unknown
- 2021-10-11 ZA ZA2021/07668A patent/ZA202107668B/en unknown
-
2022
- 2022-06-24 US US17/848,976 patent/US12103923B2/en active Active
-
2024
- 2024-08-09 US US18/799,483 patent/US20240400548A1/en active Pending